title: Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children.
abstract: OBJECTIVE
  A number of long-term research studies are in progress to evaluate the effects of treatment with GH on growth and final height in children with short stature but no demonstrable abnormality of GH secretion. Such treatment is invasive, expensive and carries some risk to the child. An early indication of growth response would allow restriction of treatment to those children most likely to benefit, but anthropometric measurements are relatively subjective, insensitive and imprecise. The aim of this study was to evaluate bone alkaline phosphatase, procollagen Type I C-terminal propeptide, procollagen Type III N-terminal propeptide and the cross-linked carboxy-terminal telopeptide of Type I collagen as early biochemical predictors of height velocity response to growth-promoting treatments in short normal children.
  
  
  METHODS
  A prospective intervention study, partially placebo controlled on a double blind basis.
  
  
  METHODS
  Fifty healthy children with familial short stature or constitutional delay in growth and puberty (8 girls, 42 boys, ages 5.5-16.5 years and all either prepubertal (45) or in very early puberty (5 boys) at the start of treatment) were treated with placebo (6), GH alone (32), GH plus oxandrolone (8) or GH plus testosterone (4).
  
  
  METHODS
  Bone alkaline phosphatase and the collagen markers were measured at the start of treatment and 3 months later. Height velocity was calculated at the start of treatment and again after one year.
  
  
  RESULTS
  Pre-treatment biochemical marker concentrations did not predict height velocity response after one year. Increments in all markers after 3 months were significantly correlated with height velocity increments after one year of treatment, the highest correlations being observed for bone alkaline phosphatase (r = 0.67, P < 0.0001) and procollagen Type III N-terminal propeptide (r = 0.57, P < 0.0001). Highly significant correlations (P < 0.0001) were also observed between bone alkaline phosphatase and procollagen Type I C-terminal propeptide (r = 0.55) and between procollagen Type III N-terminal propeptide and the cross-linked carboxy-terminal telopeptide of Type I collagen (r = 0.62). Multiple linear regression with stepwise selection of variables identified bone alkaline phosphatase and procollagen Type III N-terminal propeptide as the only two independent variables that contributed significantly to the prediction of height velocity response after one year (analysis of variance, P < 0.0001). Together they predicted 59% of the variability in height velocity response after a year.
  
  
  CONCLUSIONS
  The best early predictors of height velocity response were bone alkaline phosphatase (a protein found in hypertrophic chondrocytes in the epiphyseal growth plate, in calcifying matrix vesicles and in mature osteoblasts) and procollagen Type III N-terminal propeptide, a marker of interstitial fibril biosynthesis in soft tissues. Using these markers, GH treatment could be targeted to those children most likely to benefit in the medium term.
authors.affiliation: Department of Paediatric Biochemistry, Royal Hospital for Sick Children, Edinburgh, UK.
authors.forename: P M
authors.initials: PM
authors.lastname: Crofton
authors.forename: H F
authors.initials: HF
authors.lastname: Stirling
authors.forename: E
authors.initials: E
authors.lastname: Schönau
authors.forename: C J
authors.initials: CJ
authors.lastname: Kelnar
mesh_terms: D000293:Adolescent; D000469:Alkaline Phosphatase / Q000032:analysis*; D015415:Biomarkers / Q000032:analysis*; D001827:Body Height / Q000187:drug effects*; D001846:Bone Development / Q000187:drug effects; D001842:Bone and Bones / Q000737:chemistry / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D003094:Collagen / Q000032:analysis*; D024042:Collagen Type I; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010074:Oxandrolone / Q000627:therapeutic use; D018579:Patient Selection; D010446:Peptide Fragments / Q000032:analysis; D010455:Peptides / Q000032:analysis; D011347:Procollagen / Q000032:analysis; D011446:Prospective Studies; D013739:Testosterone / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D024042:Collagen Type I; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; C041876:procollagen Type III-N-terminal peptide; C042813:procollagen type I carboxy terminal peptide; D013739:Testosterone; D010074:Oxandrolone; D013006:Growth Hormone; D003094:Collagen; D000469:Alkaline Phosphatase